Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:liu-165529" > Dalcetrapib Reduces...

1 of 1
Previous record
Next record
To hitlist

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

Schwartz, Gregory G. (author): Vet Affairs Med Ctr, CO 80012 USA; Univ Colorado, CO 80045 USA

Leiter, Lawrence A. (author): Univ Toronto, Canada

Ballantyne, Christie M. (author): Baylor Coll Med, TX 77030 USA

Barter, Philip J. (author): Univ New South Wales, Australia

Black, Donald M. (author): DalCor Pharmaceut, Switzerland

Kallend, David (author): Medicines Co, Switzerland

Laghrissi-Thode, Fouzia (author): DalCor Pharmaceut, Switzerland

Leitersdorf, Eran (author): Hadassah Hebrew Univ, Israel

McMurray, John J. V. (author): Univ Glasgow, Scotland

Nicholls, Stephen J. (author): Monash Univ, Australia

Olsson, Anders (author): Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten

Preiss, David (author): Univ Oxford, England; Univ Oxford, England

Shah, Prediman K. (author): Cedars Sinai Heart Inst, CA USA

Tardif, Jean-Claude (author): Univ Montreal, Canada

Kittelson, John (author): Univ Colorado, CO USA

show less...

(creator_code:org_t)

2020-03-06
2020
English.
In: Diabetes Care. - : AMER DIABETES ASSOC. - 0149-5992 .- 1935-5548. ; 43:5, s. 1077-1084

Related links:: https://care.diabete...; show more...; https://urn.kb.se/re...; https://doi.org/10.2...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

OBJECTIVE Incident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis. Some data suggest that cholesteryl ester transfer protein (CETP) inhibitors reduce incident type 2 diabetes. We compared the effect of treatment with the CETP inhibitor dalcetrapib or placebo on incident diabetes in patients with recent acute coronary syndrome. RESEARCH DESIGN AND METHODS In the dal-OUTCOMES trial, 15,871 patients were randomly assigned to treatment with dalcetrapib 600 mg daily or placebo, beginning 4-12 weeks after an acute coronary syndrome. Absence of diabetes at baseline was based on medical history, no use of antihyperglycemic medication, and hemoglobin A(1c) and serum glucose levels below diagnostic thresholds. Among these patients, incident diabetes after randomization was defined by any diabetes-related adverse event, new use of antihyperglycemic medication, hemoglobin A(1c) >= 6.5%, or a combination of at least two measurements of serum glucose >= 7.0 mmol/L (fasting) or >= 11.1 mmol/L (random). RESULTS At baseline, 10,645 patients (67% of the trial cohort) did not have diabetes. During a median follow-up of 30 months, incident diabetes was identified in 403 of 5,326 patients (7.6%) assigned to dalcetrapib and in 516 of 5,319 (9.7%) assigned to placebo, corresponding to absolute risk reduction of 2.1%, hazard ratio of 0.77 (95% CI 0.68-0.88; P < 0.001), and a need to treat 40 patients for 3 years to prevent 1 incident case of diabetes. Considering only those with prediabetes at baseline, the number needed to treat for 3 years to prevent 1 incident case of diabetes was 25. Dalcetrapib also decreased the number of patients who progressed from normoglycemia to prediabetes and increased the number who regressed from diabetes to no diabetes. CONCLUSIONS In patients with a recent acute coronary syndrome, incident diabetes is common and is reduced substantially by treatment with dalcetrapib.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

Diabetes Care (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Schwartz, Gregor ...; Leiter, Lawrence ...; Ballantyne, Chri ...; Barter, Philip J ...; Black, Donald M.; Kallend, David; show more...; Laghrissi-Thode, ...; Leitersdorf, Era ...; McMurray, John J ...; Nicholls, Stephe ...; Olsson, Anders; Preiss, David; Shah, Prediman K ...; Tardif, Jean-Cla ...; Kittelson, John; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Endocrinology an ...

Articles in the publication: Diabetes Care

By the university: Linköping University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se